HRP20120108T2 - Spojevi benzoimidazol-karboksamida kao agonisti 5-ht4 receptora - Google Patents

Spojevi benzoimidazol-karboksamida kao agonisti 5-ht4 receptora Download PDF

Info

Publication number
HRP20120108T2
HRP20120108T2 HR20120108T HRP20120108T HRP20120108T2 HR P20120108 T2 HRP20120108 T2 HR P20120108T2 HR 20120108 T HR20120108 T HR 20120108T HR P20120108 T HRP20120108 T HR P20120108T HR P20120108 T2 HRP20120108 T2 HR P20120108T2
Authority
HR
Croatia
Prior art keywords
piperidin
ylmethyl
phenyl
carboxylic acid
isopropyl
Prior art date
Application number
HR20120108T
Other languages
English (en)
Croatian (hr)
Inventor
Murray Mckinnell Robert
Gendron Roland
Jiang Lan
Choi Seok-Ki
D. Long Daniel
R. Fatheree Paul
Marquess Daniel
M. Dalziel Sean
M. Phizackerley Kirsten
Original Assignee
Theravance
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120108(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance filed Critical Theravance
Publication of HRP20120108T1 publication Critical patent/HRP20120108T1/xx
Publication of HRP20120108T2 publication Critical patent/HRP20120108T2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20120108T 2005-05-25 2006-05-24 Spojevi benzoimidazol-karboksamida kao agonisti 5-ht4 receptora HRP20120108T2 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68446605P 2005-05-25 2005-05-25
US68447805P 2005-05-25 2005-05-25
US74841505P 2005-12-08 2005-12-08
PCT/US2006/020085 WO2006127815A2 (en) 2005-05-25 2006-05-24 Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Publications (2)

Publication Number Publication Date
HRP20120108T1 HRP20120108T1 (en) 2012-02-29
HRP20120108T2 true HRP20120108T2 (hr) 2012-03-31

Family

ID=37452788

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120108T HRP20120108T2 (hr) 2005-05-25 2006-05-24 Spojevi benzoimidazol-karboksamida kao agonisti 5-ht4 receptora

Country Status (26)

Country Link
US (10) US7759363B2 (enExample)
EP (1) EP1899324B1 (enExample)
JP (2) JP5072111B2 (enExample)
KR (1) KR101333280B1 (enExample)
AR (1) AR057327A1 (enExample)
AT (1) ATE535523T1 (enExample)
AU (1) AU2006250009B2 (enExample)
BR (1) BRPI0611202C1 (enExample)
CA (1) CA2607280C (enExample)
CY (1) CY1112366T1 (enExample)
DK (1) DK1899324T3 (enExample)
EA (1) EA013240B1 (enExample)
ES (1) ES2376115T3 (enExample)
HR (1) HRP20120108T2 (enExample)
IL (1) IL186883A (enExample)
MA (1) MA29541B1 (enExample)
MX (1) MX2007014762A (enExample)
MY (1) MY147756A (enExample)
NO (1) NO339658B1 (enExample)
NZ (1) NZ563068A (enExample)
PE (1) PE20061446A1 (enExample)
PL (1) PL1899324T3 (enExample)
PT (1) PT1899324E (enExample)
SI (1) SI1899324T1 (enExample)
TW (1) TWI388555B (enExample)
WO (1) WO2006127815A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1664036T3 (pl) * 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
US7256294B2 (en) * 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2010111058A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
LT2419104T (lt) * 2009-04-13 2018-02-12 Theravance Biopharma R&D Ip, Llc 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
US9676703B2 (en) 2013-08-09 2017-06-13 Santen Pharmaceutical Co., Ltd. Production method for 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and intermediate for said production method

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
ES2109190B1 (es) 1996-03-22 1998-07-01 Univ Madrid Complutense Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht
JPH111472A (ja) 1996-04-30 1999-01-06 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体及びそれを含有する医薬組成物
KR20010043032A (ko) 1998-04-28 2001-05-25 도모따께 다께시 1-[(1-치환-4-피페리디닐)메틸]-4-피페리딘 유도체, 그의제조방법, 그것을 함유하는의약조성물 및 이 화합물의중간체
TR200101239T2 (tr) 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
ES2154605B1 (es) 1999-09-14 2001-11-16 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
JP2001122784A (ja) 1999-10-27 2001-05-08 Dainippon Pharmaceut Co Ltd １−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体からなる医薬
US6552046B2 (en) * 2000-06-07 2003-04-22 Aryx Therapeutics Materials and methods for the treatment of gastroesophageal reflux disease
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
ES2285227T3 (es) 2002-08-05 2007-11-16 Eli Lilly And Company Arilbenzodiazepinas sustituidas con piperazina.
WO2004026868A1 (en) * 2002-09-20 2004-04-01 Pfizer Japan Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
JP2004277319A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物
JP2004277318A (ja) * 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
JP2004277320A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １，４−ジ置換ピペリジン誘導体およびそれを含有する医薬組成物
PL1664036T3 (pl) 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
MY147756A (en) 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
US7256294B2 (en) 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound

Also Published As

Publication number Publication date
US20150183761A1 (en) 2015-07-02
IL186883A (en) 2013-03-24
US20200283408A1 (en) 2020-09-10
BRPI0611202C1 (pt) 2021-05-25
HRP20120108T1 (en) 2012-02-29
TWI388555B (zh) 2013-03-11
MX2007014762A (es) 2008-02-14
US20130273568A1 (en) 2013-10-17
JP2008542281A (ja) 2008-11-27
JP5072111B2 (ja) 2012-11-14
US11254655B2 (en) 2022-02-22
IL186883A0 (en) 2008-02-09
WO2006127815A2 (en) 2006-11-30
US20090209582A1 (en) 2009-08-20
EA013240B1 (ru) 2010-04-30
NO20076481L (no) 2007-12-17
US10696656B2 (en) 2020-06-30
CA2607280C (en) 2013-09-17
JP2012197322A (ja) 2012-10-18
EA200702612A1 (ru) 2008-06-30
DK1899324T3 (da) 2012-02-13
US8143279B2 (en) 2012-03-27
US9975877B2 (en) 2018-05-22
MY147756A (en) 2013-01-15
US20170081313A1 (en) 2017-03-23
CA2607280A1 (en) 2006-11-30
US20190152951A1 (en) 2019-05-23
KR101333280B1 (ko) 2013-11-28
TW200716607A (en) 2007-05-01
NO339658B1 (no) 2017-01-16
US20180237420A1 (en) 2018-08-23
AU2006250009B2 (en) 2012-03-08
PT1899324E (pt) 2012-01-24
ES2376115T3 (es) 2012-03-09
US20100249186A1 (en) 2010-09-30
US9428489B2 (en) 2016-08-30
US20060270652A1 (en) 2006-11-30
BRPI0611202B8 (pt) 2019-09-24
AR057327A1 (es) 2007-11-28
MA29541B1 (fr) 2008-06-02
HK1110980A1 (en) 2008-07-25
EP1899324B1 (en) 2011-11-30
AU2006250009A1 (en) 2006-11-30
SI1899324T1 (sl) 2012-03-30
WO2006127815A3 (en) 2007-08-02
PL1899324T3 (pl) 2012-04-30
US20220274957A1 (en) 2022-09-01
US10233172B2 (en) 2019-03-19
CY1112366T1 (el) 2015-12-09
KR20080021045A (ko) 2008-03-06
ATE535523T1 (de) 2011-12-15
EP1899324A2 (en) 2008-03-19
PE20061446A1 (es) 2007-01-16
BRPI0611202B1 (pt) 2019-09-24
US7759363B2 (en) 2010-07-20
US8377964B2 (en) 2013-02-19
BRPI0611202A2 (pt) 2010-08-24
NZ563068A (en) 2011-01-28

Similar Documents

Publication Publication Date Title
JP5411927B2 (ja) Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
ES2640257T3 (es) Fenilureas y fenilamidas sustituidas como ligandos del receptor vanilloide
AU660180B2 (en) 1-acylpiperidine compounds
US9133122B2 (en) Amide compounds, compositions and uses thereof
CN102112449A (zh) 苯基或吡啶基取代的吲唑衍生物
SK82298A3 (en) Novel compounds with analgesic effect
JP2004505070A (ja) カルボキサミド化合物およびそれらのヒト１１ｃｂｙ受容体アンタゴニストとしての使用
EP1302463A1 (en) Medicine comprising dicyanopyridine derivative
JP2010520876A (ja) ピペラジンおよびピペリジンｍＧｌｕＲ５増強剤
RS57415B1 (sr) Supstituisani tiazol ili oksazol antagonisti p2x7 receptora
JP2011513295A (ja) インダゾール誘導体
RS60160B1 (sr) Fenilni derivati kao antagonisti kanabinoidnog receptora 2
JPWO2015056771A1 (ja) 含硫黄二環式化合物
JPH04321677A (ja) 新規の２−メトキシフェニルピペラジン誘導体
KR20030092008A (ko) 펩티드 데포르밀라제 저해제
IL256809A (en) A method for producing a nitrogen-containing heterocyclic compound and its intermediate
JP2008542281A5 (enExample)
JP2011500767A (ja) Ｐ２ｘ７モジュレータとしての４−ベンゾイル−１−置換ピペラジン−２−オン誘導体
BG65457B1 (bg) Пиперазинметил бензофуранови бензамиди, фармацевтичен състав, който ги съдържа, и тяхното използване като лекарствени средства
NO309813B1 (no) Nye 1-acylpiperidinforbindelser, farmasøytiske preparater inneholdende disse, samt anvendelse derav til behandling av sykdommer som viser respons pÕ antagonisering av NK1-reseptoren
JP5498482B2 (ja) アリールピラジノン（ａｒｙｌｐｙｒａｚｉｎｏｎｅ）誘導体インスリン分泌刺激薬、それを得る方法、および糖尿病の治療のためのその使用
JP5815874B2 (ja) Ｈｄｌコレステロール上昇剤としての３−ピリジンカルボン酸ヒドラジド
EP2200982B1 (en) Piperidine derivatives as nk3 receptor antagonists
JP3786983B2 (ja) ピロリジノン誘導体
CA2641817A1 (en) Novel dual nk2/nk3-antagonists, pharmaceutical compositions comprising them and processes for their preparation